Gosset Anti-GD2 monoclonal antibody Overview
Anti-GD2 antibodies are monoclonal antibodies engineered to recognize and bind to GD2, a cell surface disialoganglioside found at high density on a range of neuroectodermal and epithelial tumors, most notably neuroblastoma, melanoma, and some sarcomas. Their clinical rationale derives from the restricted expression of GD2 in normal tissues, making it a tumor-selective target. Upon binding GD2, these antibodies trigger immune-mediated lysis of tumor cells via ADCC, CDC, and in some cases, direct induction of apoptosis. Several anti-GD2 antibodies have been developed, including murine, chimeric, and humanized forms, with dinutuximab being an FDA-approved therapy for high-risk neuroblastoma. Despite clinical benefits, anti-GD2 antibody therapies are associated with notable toxicities, particularly pain and neuropathy, reflecting GD2’s expression in peripheral nerves. Research continues to develop agents with reduced toxicity and increased efficacy, as well as to broaden their use to additional GD2-positive cancers.
Mechanism of Action
Antibody-dependent cell-mediated cytotoxicity (ADCC); Complement-dependent cytotoxicity (CDC); Direct induction of apoptosis and cell death of GD2-expressing tumor cells; Phagocytosis by immune cells
Biological Functions
Disease Associations
Safety Considerations
- Neuropathic pain and peripheral neuropathy (due to GD2 expression in nerves)
- Allergic reactions and hypersensitivity
- Development of human anti-mouse antibody (HAMA) response (especially with murine or chimeric antibodies)
- Neurotoxicity
Interacting Drugs
Associated Biomarkers
| Biomarker |
|---|
| GD2 expression (by immunohistochemistry or FACS) in tumor tissue |